NUWIQ PUP Study

The largest prospective clinical trial of a single FVIII product in previously untreated patients with hemophilia A.

Review the NuProtect Study and Findings

News & stories

Check out our latest stories

FDA Orphan Drug Approval: Octapharma’s Octagam® 10% Receives 7 Years of Market Exclusivity for Adult Dermatomyositis

Octagam® 10% Expected to Become the First Treatment Option for Adults with Rare Immune-mediated Inflammatory Disease

FDA Approves Octapharma's Octagam®10% for Adult Dermatomyositis

FDA Approval Based on Positive Results of International, Multi-center ProDERM Study

FDA Approvals Strengthen Octapharma USA Pediatric Critical Care Product Portfolio

Octaplas™ and fibryga® receive new product labeling following FDA’s approval of BLA supplements to update therapy research

Octapharma USA Presents Research on Congenital & Acquired Bleeding Disorders at ASH Annual Meeting

Research evaluates use of fibryga®, Octaplas™, and Octaplex® as investigational therapies

Patient engagement

Octapharma takes an active role in our community

We sponsor and support organizations worldwide.

Learn how we engage with patients

Our products

Products

Learn more about our products to treat rare diseases and other coagulopathies and bleeding disorders.